One of the latest companies to hit the public market is Caris Life Sciences (CAI). Pricing its IPO at $21 per share, Caris ...

The cancer diagnostics and treatment company priced shares above their earlier target range and might signal a renewed ...

The stock of Caris Life Sciences shined in its Nasdaq debut on Wednesday, pricing its heavily-subscribed initial public ...

Caris Life Sciences Inc., a health-care company that uses technology to help diagnose and treat cancer, raised $494 million ...

Caris Life Sciences® (Caris), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, ...

The successful IPO of Caris Life Sciences makes its founder David Dean Halbert worth an estimated $3.3 billion.

Caris Life Sciences Inc., a health care company that uses technology to help diagnose and treat cancer, raised $494 million ...

David Dean Halbert, Caris Life Sciences chairman, founder and CEO, joins 'Squawk Box' to discuss the company's IPO debut, how ...

Cancer-testing company raises $494 million in initial public offering.

Caris Life Sciences bumped up the pricing of its IPO to raise more than $494.1 million in its Nasdaq debut—well over the ...

Caris Life Sciences is experiencing rapid growth, leveraging AI and molecular science for personalized medicine. Click here ...

Caris Life Sciences raised $494.1 million in its Nasdaq initial public offering, the cancer diagnostic firm said on Tuesday, ...